A pooled analysis of 1,144 patients with HIV-associated lymphoma: Assessment of lymphoma-, HIV-, and treatment-specific factors on clinical outcomes.
Stefan K. Barta(University of Pennsylvania), Joseph A. Sparano(Tisch Cancer Institute), Mireia Morgades(Josep Carreras Leukaemia Research Institute), Wyndham H. Wilson(National Institutes of Health), Richard F. Little(Dana-Farber Cancer Institute), José‐Tomás Navarro(Universitat Autònoma de Barcelona), Lawrence D. Kaplan(UCSF Helen Diller Family Comprehensive Cancer Center), Kieron Dunleavy(National Cancer Institute), Lee Ratner(Washington University in St. Louis), Jeanette Y. Lee(University of Arkansas for Medical Sciences), Michele Spina(National Cancer Institute), Josep‐María Ribera(Universitat Autònoma de Barcelona), Roni Tamari(Memorial Sloan Kettering Cancer Center), Christoph Wyen, Xiaonan Xue(Albert Einstein College of Medicine), Olga García(Institut Català d'Oncologia), François Boué(Inserm), Nicolas Mounier(Centre Hospitalier Universitaire de Nice), Rudolf Weiß, Lionel Galicier(Hôpital de la Timone)
Cited by 1
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k